Lowered costs and incremental effectiveness could improve when using biomarker-guided selection for treatment of patients with metastatic colorectal cancer using first-line nivolumab. Choosing the ...
Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with homologous recombination repair–altered metastatic hormone-sensitive prostate ...
TAS-102 plus bevacizumab is cost-effective in China but not in the US or UK due to high incremental cost-effectiveness ratios (ICERs). The study uses a decision model to compare TAS-102 monotherapy ...
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal ...
We identified 5,688 patients with aNSCLC who received MGPS (n = 875) or SMGT (n = 4,813), of which 22% tested positive for epidermal growth factor receptor (18.5% MGPS; 17.3% SMGT) or anaplastic ...
Usual care provided 9.59 QALYs at a lifetime cost of $222,300, diet and exercise yielded 9.75 QALYs for $226,300, and semaglutide offered 10.48 QALYs at $273,500, with tirzepatide providing 10.68 ...
A detailed analysis in the Canadian Journal of Cardiology of the cost-effectiveness of semaglutide shows that with price reductions, it could meet the benchmark for healthcare value, urging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results